These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 33491326)
1. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway. Li F; Gu F; Li Q; Zhai C; Gong R; Zhu X J Biochem Mol Toxicol; 2021 May; 35(5):e22726. PubMed ID: 33491326 [TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. Song L; Zhou Z; Gan Y; Li P; Xu Y; Zhang Z; Luo F; Xu J; Zhou Q; Dai F J Cell Biochem; 2019 Jun; 120(6):9656-9666. PubMed ID: 30548308 [TBL] [Abstract][Full Text] [Related]
3. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Tang Y; Xiao G; Chen Y; Deng Y Anticancer Drugs; 2018 Sep; 29(8):725-735. PubMed ID: 29916897 [TBL] [Abstract][Full Text] [Related]
4. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. Gong T; Cui L; Wang H; Wang H; Han N J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734 [TBL] [Abstract][Full Text] [Related]
5. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer. Ma T; Chen H; Wang P; Yang N; Bao J Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162 [No Abstract] [Full Text] [Related]
6. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Zhou Y; Li S; Li J; Wang D; Li Q Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819 [TBL] [Abstract][Full Text] [Related]
7. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway. Gao BB; Wang SX Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077 [TBL] [Abstract][Full Text] [Related]
8. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway. Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766 [TBL] [Abstract][Full Text] [Related]
9. Exosomal lncRNA FOXD3-AS1 upregulates ELAVL1 expression and activates PI3K/Akt pathway to enhance lung cancer cell proliferation, invasion, and 5-fluorouracil resistance. Mao G; Mu Z; Wu DA Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1484-1494. PubMed ID: 34605863 [TBL] [Abstract][Full Text] [Related]
10. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway. Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493 [TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA DDX11-AS1 promotes non-small cell lung cancer development via regulating PI3K/AKT signalling. Feng X; Yang S; Zhou S; Deng S; Xie Y Clin Exp Pharmacol Physiol; 2020 Sep; 47(9):1622-1631. PubMed ID: 32298476 [TBL] [Abstract][Full Text] [Related]
12. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression. Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225 [TBL] [Abstract][Full Text] [Related]
13. LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of non-small cell lung cancer cells by inactivating PI3K/Akt pathway. Gao T; Dai X; Jiang Y; He X; Yuan S; Zhao P Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 32975291 [TBL] [Abstract][Full Text] [Related]
14. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Shi H; Pu J; Zhou XL; Ning YY; Bai C Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375 [TBL] [Abstract][Full Text] [Related]
15. lncRNA ADAMTS9-AS1 promotes bladder cancer cell invasion, migration, and inhibits apoptosis and autophagy through PI3K/AKT/mTOR signaling pathway. Yang G; Li Z; Dong L; Zhou F Int J Biochem Cell Biol; 2021 Nov; 140():106069. PubMed ID: 34428588 [TBL] [Abstract][Full Text] [Related]
16. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway. Ma X; Ren H; Zhang Y; Wang B; Ma H Environ Toxicol; 2022 Dec; 37(12):3013-3027. PubMed ID: 36125241 [TBL] [Abstract][Full Text] [Related]
17. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
18. Prostaglandin transporter, SLCO2A1, mediates the invasion and apoptosis of lung cancer cells via PI3K/AKT/mTOR pathway. Zhu Q; Liang X; Dai J; Guan X Int J Clin Exp Pathol; 2015; 8(8):9175-81. PubMed ID: 26464663 [TBL] [Abstract][Full Text] [Related]
19. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway. Zhao L; Zhang J; Fan Y; Li Y Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA-520a-3p inhibits cell growth and metastasis of non-small cell lung cancer through PI3K/AKT/mTOR signaling pathway. Lv X; Li CY; Han P; Xu XY Eur Rev Med Pharmacol Sci; 2018 Apr; 22(8):2321-2327. PubMed ID: 29762835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]